Much like cannabis, the legalization of psilocybin is enjoying increasing support in the United States.
Up to 38% of adults in the US believe psilocybin mushrooms should be legal, according to new study from research firm Green Horizons High Times. Up to 25% of respondents say that psilocybin should be legal in limited circumstances.
Survey Indicates Psilocybin Mushrooms Are Growing In The United States
“When it comes to psychedelics, there are many parallels with the movement to legalize cannabis. Either way, education is paramount, ”said Adriana Waterston of Green Horizon Insights and Strategy, in a press release.
“Psychedelics, like cannabis, have been linked to a negative and highly stigmatized image for many years. However, science shows us that psychedelics hold great promise for some chronic psychological illnesses, even those that have resisted treatment. As we continue to study psychedelics and the evidence for their benefits accumulates, we can expect support for legalization to follow. ”
Additionally, psilocybin is fast becoming one of the most popular topics in the medical research community, in the press, and even among investors.
Even states in the United States have started to decriminalize the use of psilocybin, including Denver, Oakland and Santa Cruz which have just decriminalized possession of products containing psilocybin or psilocybin. Washington DC could vote by November 2020 to legalize it as well.
Much like clinical trials from major institutions find that psychedelic treatments, like psilocybin mushrooms, can effectively treat obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, eating disorders, depression, anxiety and maybe even weight loss. In fact, it could very well help treat the 30 million Americans who currently suffer from an eating disorder.
Psilocybin, a possible treatment for weight loss
NeonMind, the majority subsidiary of Yield Growth Corp has filed a provisional patent application in the United States for the invention relating to the therapeutic administration of psilocybin or psilocin, combined with a therapeutic supportive treatment for a patient in order to provide him with benefits in terms of weight loss and treatment of related health problems.
The provisional patent relates to a psilocybin-based guided psychedelic therapy protocol using psychotherapy before, during and after the psychoactive effects of psilocybin are experienced by the patient. Psychedelic-assisted psychotherapy is designed to help learn from positive psychedelic experiences, integrate them into daily life, and help plan, prepare, and make sense of psychedelic experiences for therapeutic outcome.
In addition, NeonMind has contracted research organization Translational Life Sciences Inc. to design and plan a first preclinical study using psilocybin which is expected to begin in the fall of 2020. The preclinical study is expected to provide data to design the phase. 2 clinical trials in humans to test psilocybin as a treatment for weight loss. Phase 2 clinical trials are expected to begin in 2021, subject to obtaining all required regulatory approvals.